February 4, 2009

Cellartis signs licence deal with ITI life Sciences to commercialise large scale hES cell production

The technology being licensed was developed as part of an ongoing three-year ITI programme, launched in January 2007, to develop an automated process for producing large volumes of high-quality, ethically-derived human embryonic (hES) stem cell lines (i.e. cells with the potential to become any type of cell). This technology has the potential of driving unprecedented innovation in drug discovery and regenerative medicine today and in the future.

Mats Lundwall, CEO of Cellartis, said: “We are very proud of our involvement in ITI’s Stem Cell Technology Programme and delighted that we have secured this licensing deal. Our involvement in the programme has been a strong catalyst for our growth and we look forward to delivering more success together, in Scotland and beyond. Our time in Scotland has been very rewarding and long may it continue. It’s a great time for positive news flow in Stem Cells with political, regulatory and commercial announcements all pointing to a positive future for Cellartis and its partners.”